How is QCS Staffing supporting clients to develop a Covid-19 vaccine?

Now as part of our business response to Covid-19, we’re working at pace to help clients plan and develop coronavirus vaccines.

QCS Staffing has delivered to the life sciences sector since 2002, providing specialist staffing solutions to the biopharmaceutical, pharmaceutical and medical device industry. We’re approved suppliers to nine of the top ten biopharmaceutical organisations globally and are proud to support them with their vaccine development, scale-up, manufacturing and product launches. 

One of the largest vaccine projects we’ve worked on was with Novartis, helping to develop a vaccine for Swine Flu. We were able to deliver large volumes of expert vaccine and biotech professionals to support projects and operations in the UK, US, Germany and Italy.  We delivered 52 specialist consultants to Novartis Vaccines to support in developing and manufacturing three (A)H1N1 vaccines that were distributed globally.

We also work with GSK on an ongoing basis throughout their global vaccine network GSK Vaccines. The work here is primarily with a focus on capital investment portfolios and manufacturing drugs and vaccines on a commercial scale. Capital projects, quality assurance and remediation has been the core focus of our partnership to Pfizer’s vaccine business over the past 15 years, while working with AstraZeneca has involved large scale engineering projects to add capacity for vaccine manufacturing.  We have also partnered multiple vaccine organisations in sourcing regulatory affairs consultants for CMC activities and BLAs (biologics license applications).

Our talent base spans everything from medical writers, pharmacovigilance and drug safety professionals through to project management, engineering, manufacturing and technical operations support, with plenty in between. We’re proud of our expertise to be able to deliver high-quality contractors for the full life cycle of a vaccine from research and development; regulatory; manufacturing, science & technology; capital projects and engineering; to validation & quality.  As most vaccine development is in the early stages currently, we anticipate delivering R&D, pharmacovigilance and regulatory talent in the near future, with capital project, engineering and quality assurance skills to follow. 

We’re also seeing organisations testing existing drugs for efficacy in the coronavirus fight, so we expect to see technical experts being brought on board to help with testing in this area. In addition, clients will likely look at repurposing their existing sites and projects specifically for Covid-19 vaccine development, mobilising their existing workforce back to site as well as identifying new talent to help with this next phase.

Our proven history of staffing the drug development and drug manufacturing industries, coupled with our successes in vaccines with some of the market’s biggest leaders in pharmaceuticals, gives us an unparalleled access to a vast array of highly skilled professionals with specific vaccine expertise. Our consultants are experts in their fields and maintain a vested interest in industry news and developments, allowing us to better support candidates and clients in this ever-changing marketplace. 

With a network of qualified and vetted professionals all over the world, our reach is truly global. This gives us the unique ability to deliver to Covid-19 vaccine projects all over the world, which is critical given that 210 countries and territories have now reported cases of the virus. We can deliver skilled resource all over the world compliantly, with processes and tools already in place to do so – not to mention our extensive network of highly trusted, highly skilled individuals who are ready to hit the ground running. If you are developing a vaccine or need specialist support in ramping up for manufacture, we’d love to help.